<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        143-9-16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SEEBRI BREEZHALER
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GLYCOPYRRONIUM BROMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Inhalation use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS PHARMA AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03BB06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Seebri Breezhaler is</strong></p><p>This medicine contains an active substance called glycopyrronium bromide. This belongs to a group of medicines called bronchodilators.</p><p>&nbsp;</p><p><strong>What Seebri Breezhaler is used for</strong></p><p>This medicine is used to make breathing easier for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease (COPD). When you inhale it, it helps you breathe more easily.</p><p>&nbsp;</p><p>If you use this medicine once a day, it will help to reduce the effects of COPD on your everyday life.</p><p>&nbsp;</p><p>In COPD the muscles around the airways tighten. This makes breathing difficult. This medicine blocks the tightening of these muscles in the lungs, making it easier for air to get in and out of the lungs.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not use Seebri Breezhaler</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to glycopyrronium bromide or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p><strong>b. Warnings and precautions</strong></p><p>Talk to your doctor before using Seebri Breezhaler, if any of the following applies to you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have kidney problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have an eye problem called narrow‑angle glaucoma.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have difficulty passing urine.</p><p>&nbsp;</p><p><strong>c. During treatment with Seebri Breezhaler, </strong>stop taking this medicine and tell your doctor immediately:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience tightness of the chest, coughing, wheezing or breathlessness immediately after using Seebri Breezhaler (signs of bronchospasm).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience difficulties in breathing or swallowing, swelling of the tongue, lips or face, skin rash, itching and hives (signs of allergic reaction).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes. These may be signs of an acute attack of narrow‑angle glaucoma.</p><p>&nbsp;</p><p>Seebri Breezhaler is used as a maintenance treatment for your COPD. Do not use this medicine to treat a sudden attack of breathlessness or wheezing.</p><p>&nbsp;</p><p><strong>d. Children and adolescents</strong></p><p>Do not give this medicine to children or adolescents below the age of 18&nbsp;years.</p><p>&nbsp;</p><p><strong>e. Other medicines and Seebri Breezhaler</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines similar to Seebri Breezhaler used for your lung disease, such as ipratropium, oxitropium or tiotropium (so called anticholinergics).</p><p>&nbsp;</p><p>No specific side effects have been reported when Seebri Breezhaler has been taken together with other products used to treat COPD such as reliever inhalers (e.g. salbutamol), methylxanthines (e.g. theophylline) and/or oral and inhaled steroids (e.g. prednisolone).</p><p>&nbsp;</p><p><strong>f. Pregnancy, breast‑feeding and fertility</strong></p><p>There are no data from the use of this medicine in pregnant women and it is not known whether the active substance of this medicine passes into human milk.</p><p>&nbsp;</p><p>If you are pregnant or breast‑feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>g. Driving and using machines</strong></p><p>It is unlikely that this medicine will affect your ability to drive and use machines.</p><p>&nbsp;</p><p><strong>h. Seebri Breezhaler</strong><strong> contains lactose</strong></p><p>This medicine contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How much Seebri Breezhaler to use</strong></p><p>The usual dose is to inhale the content of one capsule each day.</p><p>You only need to inhale once a day because the effect of this medicine lasts for 24&nbsp;hours.</p><p>Do not use more than your doctor tells you to use.</p><p>&nbsp;</p><p><strong>Older people</strong></p><p>You can use this medicine if you are aged 75&nbsp;years and over at the same dose as for other adults.</p><p>&nbsp;</p><p><strong>When to inhale Seebri Breezhaler</strong></p><p>Use this medicine at the same time each day. This will also help you to remember to use it.</p><p>&nbsp;</p><p><strong>Seebri Breezhaler with food and drink</strong></p><p>You can inhale this medicine anytime before or after food or drink.</p><p>&nbsp;</p><p><strong>How to inhale Seebri Breezhaler</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In this pack, you will find an inhaler and capsules (in blisters) that contain the medicine as inhalation powder. Only use the capsules with the inhaler provided in this pack (Seebri Breezhaler inhaler). The capsules should remain in the blister until you need to use them.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not push the capsule through the foil.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When you start a new pack, use the new Seebri Breezhaler inhaler that is supplied in the pack.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dispose of each inhaler after 30&nbsp;days of use.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not swallow the capsules.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please read the instructions at the end of this leaflet for more information on how to use the inhaler.</p><p>&nbsp;</p><p><strong>a. If you use more Seebri Breezhaler than you should</strong></p><p>If you have inhaled too much of this medicine<em> </em>or if someone else accidentally uses your capsules, you must immediately either tell your doctor or go to the nearest emergency unit. Show the pack of Seebri Breezhaler. Medical attention may be needed.</p><p>&nbsp;</p><p><strong>b. If you forget to use Seebri Breezhaler</strong></p><p>If you forget to inhale a dose, take one as soon as possible. However, do not take two doses on the same day. Then take the next dose as usual.</p><p>&nbsp;</p><p><strong>How long to continue your treatment with Seebri Breezhaler</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep using this medicine for as long as your doctor tells you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; COPD is a long‑term disease and you should use this medicine every day and not only when you have breathing problems or other symptoms of COPD.</p><p>If you have questions about how long to continue your treatment with this medicine, talk to your doctor or pharmacist.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Some side effects may be serious but are uncommon</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High level of blood sugar (hyperglycaemia: typical symptoms include excessive thirst or hunger and frequent urination)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, itching, hives, difficulty breathing or swallowing, dizziness (possible signs of allergic reaction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling mainly of the tongue, lips, face or throat (possible signs of angioedema)</p><p>If you get any of these side effects, tell your doctor immediately.</p><p>&nbsp;</p><p><strong>Some side effects may be serious, but the frequency of these side effects is unknown</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty breathing with wheezing or coughing (signs of paradoxical bronchospasm)</p><p>&nbsp;</p><p><strong>Some side effects are common</strong></p><p><em>(may affect up to 1 in 10&nbsp;people)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Runny or stuffy nose, sneezing, sore throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea or stomach ache</p><p>&nbsp;</p><p><strong>Some side effects are uncommon</strong></p><p><em>(may affect up to 1 in 100&nbsp;people)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty and pain when passing urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painful and frequent urination</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough with sputum</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dental caries</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling of pressure or pain in the cheeks and forehead</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nose bleeds</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in arms or legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in muscles, bones or joints of the chest</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach discomfort after meals</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Throat irritation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Voice alteration (hoarseness)</p><p>&nbsp;</p><p>Some elderly patients above 75&nbsp;years of age experienced headache (frequency common) and urinary tract infection (frequency common).</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (as mentioned under Section 6.b). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and blister after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store the capsules in the original package in order to protect from moisture and do not remove until immediately before use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each inhaler should be disposed of after 30&nbsp;days of use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you notice that the pack is damaged or shows signs of tampering.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is glycopyrronium bromide. Each capsule contains 63&nbsp;micrograms of glycopyrronium bromide (equivalent to 50&nbsp;micrograms glycopyrronium). The delivered dose (the dose that leaves the mouthpiece of the inhaler) is equivalent to 44&nbsp;micrograms of glycopyrronium.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients of the inhalation powder<strong> </strong>are lactose monohydrate and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                In this pack, you will find a device called an inhaler, together with capsules in blisters. Each blister contains either 6 or 10 hard capsules. The capsules are transparent and orange and contain a white powder. They have the product code “GPL50” printed in black above and a company logo ( ) printed in black below a black bar.

The following pack size is available:
Single pack containing 30x1 hard capsules, together with one inhaler.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.&nbsp;<br />www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05-2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو سيبري<sup>&trade;</sup> بريزهيلير<sup>&reg;</sup></strong></p><p dir="RTL">يحتوي سيبري بريزھيلر على مادة فعالة تُسمى جليكوبيرونيوم بروميد. وينتمي ھذا الدواء إلى فئة من الأدوية تُسمى موسعات الشعب الهوائية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما دواعي استعمالات </strong><strong>سيبري<sup>&trade;</sup> بريزهيلير<sup>&reg;</sup></strong></p><p dir="RTL">يُستخدم سيبري بريزھيلر في تسھيل التنفس للأشخاص البالغين الذين يعانون من صعوبات في التنفس بسبب مرض رئوي يُسمى مرض الانسداد الرئوي المزمن (COPD). عندما تستنشق ھذا الدواء، فإنه يساعدك على التنفس بسھولة أكثر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا استخدمت سيبري بريزھيلر مرة واحدة في اليوم، فإنه سيساعد على تقليل آثار مرض الانسداد الرئوي المزمن على حياتك اليومية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة مرض الانسداد الرئوي المزمن، يحدث إنقباض في العضلات المحيطة بممرات الھواء في الرئتين مما يجعل التنفس صعبًا. ويعمل سيبري بريزھيلر على منع إنقباض تلك العضلات في الرئتين، مما يُسھِّل دخول الھواء إلى الرئتين وخروجه منھما.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أ. لا تستعمل سيري بريزهيلر </strong></p><p dir="RTL">إذا كانت لديك حساسية من جليكوبيرونيوم بروميد أو أي من المكونات الأخرى لهذا الدواء (مذكورة في قسم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب. المحاذير والاحتياطات </strong></p><p dir="RTL">قبل استعمال الدواء سيبري بريزھيلر، أخبر الطبيب إذا كانت إحدى<strong><em> </em></strong>الحالات التالية تنطبق عليك:</p><ul><li dir="RTL">إذا كنت تعاني من مشكلات في الكلى</li><li dir="RTL">تعاني من مرض في العين يُسمى الزرق ضيق الزاوية</li><li dir="RTL">تعاني من صعوبة في التبول.</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ج. أثناء</strong><strong> </strong><strong>العلاج</strong><strong> </strong><strong>باستخدام</strong><strong> </strong><strong>سيبري</strong><strong> </strong><strong>بريزھيلر، </strong>توقف عن تناول هذا الدواء وأخبر طبيبك على الفور:</p><ul><li dir="RTL"><strong>إ</strong>ذا حدث ضيق في الصدر أو سعال أو أزيز في التنفس أو انقطاع التنفس عقب استخدام سيبري بريزھيلر مباشرة (علامات على تشنج في القصبة الهوائية.</li><li dir="RTL">إذا حدث صعوبة في التنفس أو البلع، تورم اللسان، الشفتين أو الوجه، طفح جلدي، حكة وتهيج في الجلد (علامات التفاعل الأرجي).</li><li dir="RTL">في حالة الشعور بألم في العين أو عدم ارتياح، أو تشوش مؤقت في الرؤية، أو رؤية ھالات أو صور ملونة مع احمرار العينين؛ فقد تكون ھذه علامات على نوبة حادة من الزرق ضيق الزاوية.</li></ul><p dir="RTL">يُستخدم سيبري بريزھيلر كعلاج دائم لحالة الانسداد الرئوي المزمن. لا تستخدم سيبري بريزھيلر لعلاج نوبات انقطاع التنفس المفاجئة أو الأزيز المفاجئ في الصدر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>د. الأطفال</strong><strong> </strong><strong>والمراھقون </strong></p><p dir="RTL">ينبغي عدم استخدام سيبري بريزھيلر في المرضى الذين تقل أعمارھم عن 18 سنة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>هـ. استخدام</strong><strong> </strong><strong>أدوية</strong><strong> </strong><strong>أخرى وسيبري بريزهيلر</strong></p><p dir="RTL">أخبر الطبيب أو الصيدلي إذا كنت تتناول حاليًا - أو تناولت مؤخرًا - أي أدوية أخرى. &nbsp;يشمل ھذا الأدوية المشابھة لسيبري بريزھيلر المستخدمة لعلاج أمراض الرئة ، مثل إبراتروبيوم أو أوكسيتروبيوم أو تيوتروبيوم (يُطلق على ھذه الأدوية أيضًا اسم مضادات الفعل الكوليني).</p><p dir="RTL">لا يوجد أعراض جانبية معينة تم الإبلاغ عنها عند استعمال سيبري بريزهيلر مع أدوية أخرى تستخدم لعلاج الالتهاب الرئوي المزمن مثل البخاخات المخففة (مثل: سالبيتامول)، ميثايلزانثينز (مثال: ثايوفيلين) و/أو الستيرويدات الفموية والمستنشقة (مثال: بريدنيزولون).&nbsp;&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>و. الحمل</strong><strong> </strong><strong>والرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL">لا توجد معلومات عن استعمال هذا الدواء في النساء الحوامل، ومن غير المعلوم إذا كانت المادة الفعالة لهذا الدواء تمر إلى حليب الأم.</p><p dir="RTL">إذا كنتِ حاملاً أو تظنين أنك قد تكونين حاملاً أو كنتِ تخططين لإنجاب طفل أو إذا كنتِ تُرضعين رضاعة طبيعية، فأخبري الطبيب بذلك قبل استعمال هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ز. القيادة وتشغيل الآلات </strong></p><p dir="RTL">من غير المرجح أن يؤثر هذا الدواء في قدرتك على القيادة وتشغيل الآلات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ح. يحتوي سيبري بريزهيلر على اللاكتوز</strong></p><p dir="RTL">يحتوي هذا الدواء على اللاكتوز. إذا أخبرك طبيبك أن لديك عد تحمل لبعض أنواع السكريات، اتصل بطبيبك قبل البدء باستعمال هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ينبغي الحرص دائمًا على استعمال ھذا الدواء حسب إرشادات الطبيب أو الصيدلي تمامًا بتمام. ينبغي استشارة الطبيب أو الصيدلي في حالة عدم التأكد من كيفية الاستخدام.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مقدار</strong><strong> </strong><strong>الجرعة</strong><strong> </strong><strong>المستنشقة</strong><strong> </strong><strong>من</strong><strong> </strong><strong>سيبري</strong><strong> </strong><strong>بريزھيلر</strong></p><p dir="RTL">الجرعة العادية ھي استنشاق محتويات كبسولة واحدة كل يوم. لا تتناول جرعة أكبر من التي يأمرك الطبيب بتناولھا.</p><p dir="RTL">ينبغي استنشاق جرعة واحدة من سيبري بريزھيلر في اليوم الواحد حيث إن مفعول الجرعة يستمر على مدار 24 ساعة.</p><p dir="RTL">لا تستعمل أكثر مما وصف لك الطبيب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كبار السن</strong></p><p dir="RTL">تستطيع استعمال هذا الدواء إذا كنت تبلغ من العمر 75 سنة فأكثر بنفس الجرعة المستخدة للبالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موعد</strong><strong> </strong><strong>استنشاق</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>سيبري</strong><strong> </strong><strong>بريزھيلر</strong></p><p dir="RTL">إن المحافظة على استنشاق جرعة سيبري بريزھيلر في وقت ثابت و محدد كل يوم سيساعدك على تذكر الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سيبري</strong><strong> </strong><strong>بريزھيلر مع الطعام والشراب</strong></p><p dir="RTL">تستطيع استنشاق هذا الدواء أي وقت قبل أو بعد الطعام أو الشراب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية استنشاق سيبري بريزهيلر</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><ul><li dir="RTL">تحتوي عبوة سيبري بريزهيلر على جھاز استنشاق وكبسولات (في شرائط &nbsp;منفصلة) بداخلها الدواء كمسحوق للاستنشاق.<strong><em> </em></strong></li></ul><ul><li dir="RTL">ينبغي عدم استخدام أي جھاز استنشاق غير الموجود في عبوة ھذا الدواء (جھاز استنشاق سيبري بريزھيلر) لاستنشاق المسحوق الموجود في الكبسولات. ينبغي دائمًا الحفاظ على الكبسولات بداخل<strong><em> </em></strong>الأشرطة المنفطة وعدم إخراجھا إلا قبل الاستخدام مباشرة.</li><li dir="RTL">لا تدفع الكبسولة من خلال رقاقة الغلاف.</li><li dir="RTL">عند البدء بإستخدام عبوة جديدة من الدواء، استخدم جھاز استنشاق سيبري بريزھيلر الجديد المرفق في العبوة الجديدة.</li><li dir="RTL">ينبغي التخلص من كل جھاز استنشاق بعد 30 &nbsp;يومًا من الاستخدام.</li><li dir="RTL">لا تبتلع الكبسولات.</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي الحرص والتأكد من قراءة التعليمات<strong> </strong>الخاصة بكيفية استخدام جھاز استنشاق سيبري بريزھيلر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أ. في</strong><strong> </strong><strong>حالة</strong><strong> </strong><strong>استنشاق</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>من</strong><strong> </strong><strong>سيبري</strong><strong> </strong><strong>بريزھيلر</strong><strong> </strong><strong>أكبر</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الجرعة</strong><strong> </strong><strong>الموصى</strong><strong> </strong><strong>بھا</strong></p><p dir="RTL">في حالة استنشاق جرعة كبيرة للغاية من سيبري بريزھيلر، أو في حالة استخدام شخص آخر لھذا الدواء دون قصد، ينبغي القيام مباشرة إما بالاتصال بالطبيب أو الذهاب إلى أقرب وحدة إسعاف.</p><p dir="RTL">&nbsp;ينبغي إحضار عبوة الدواء سيبري بريزھيلر وإظھارھا للطبيب المعالج. قد يستلزم الأمر اتخاذ إجراءات العناية الطبية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ب. في</strong><strong> </strong><strong>حالة</strong><strong> </strong><strong>نسيان</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>سيبري</strong><strong> </strong><strong>بريزھيلر</strong></p><p dir="RTL">في حالة نسيان جرعة، ينبغي تناول جرعة في أسرع وقت ممكن ولكن لا ينبغي تناول جرعتين في يوم واحد. بعد ذلك، استمر في تناول الجرعة بشكل عادي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مدة</strong><strong> </strong><strong>الاستمرار</strong><strong> </strong><strong>في</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>الدواء</strong><strong> </strong><strong>سيبري</strong><strong> </strong><strong>بريزھيلر</strong></p><ul><li dir="RTL">ينبغي الاستمرار في استعمال سيبري بريزھيلر طالما يأمرك الطبيب بذلك.</li><li dir="RTL">يُعد مرض الانسداد الرئوي المزمن من الأمراض طويلة المدى، وينبغي للمريض استخدام سيبري بريزھيلر كل يوم وليس فقط عند الشعور بصعوبة في التنفس أو حدوث أي أعراض أخرى لمرض الانسداد الرئوي المزمن.</li><li dir="RTL">إذا كان لديك أسئلة عن مدة العلاج بإستخدام<em> </em>سيبري بريزھيلر، فتحدث إلى الطبيب أو الصيدلي.</li></ul><p dir="RTL">إذا كانت لديك أسئلة أخرى عن طريقة استعمال هذا الدواء، إسأل طبيبك، الصيدلي أو الممرض.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، قد يعاني المرضى الذين يتناولون سيبري بريزھيلر من آثار جانبية، وإن كانت لا تصيب جميع الأشخاص.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قد</strong><strong> </strong><strong>تكون</strong><strong> </strong><strong>بعض</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>خطيرة لكنها غير شائعة</strong></p><ul><li dir="RTL">عدم انتظام ضربات القلب</li><li dir="RTL">إرتفاع مستوى السكر في الدم (ارتفاع السكر في الدم؛ الأعراض النموذجية تشمل العطش الشديد أو الجوع وكثرة التبول)</li><li dir="RTL">طفح جلدي ، تهيج في الجلد، صعوبة في التنفس أو البلع، دوخة (أعراض محتملة للتفاعل الأرجي).</li><li dir="RTL">تورم خاصة في اللسان، الشفتين، الوجه أو الحلق (أعراض محتملة للوذمة الوعائية).</li></ul><p dir="RTL">إذا أُصبت بأي عرض من ھذه الأعراض، قم بإبلاغ الطبيب على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد</strong><strong> </strong><strong>تكون</strong><strong> </strong><strong>بعض</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>خطيرة ولكن معدل حدوثها غير معروف</strong></p><ul><li dir="RTL">صعوبة في التنفس مع تصفير أو كحة (أعراض لتشنج القصبي المتناقض)</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بعض</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>تكون</strong><strong> </strong><strong>شائعة</strong></p><p dir="RTL">يمكن أن تؤثر في شخص واحد من كل10 أشخاص</p><ul><li dir="RTL">جفاف الفم</li><li dir="RTL">صعوبة في النوم</li><li dir="RTL">سيلان الأنف أو انسداده، عطس، التھاب الحلق</li><li dir="RTL">إسھال وألم في البطن</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بعض</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>تكون</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>شائعة</strong></p><p dir="RTL">يمكن أن تؤثر في شخص واحد من كل100 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة وألم في التبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبول مؤلم ومتكرر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان</p><ul><li dir="RTL">طفح جلدي</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال مع بلغم</p><ul><li dir="RTL">تسوس الأسنان</li><li dir="RTL">شعور بضغط أو ألم في الخدين والجبھة</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في الأنف</p><ul><li dir="RTL">ألم في الذراعين أو القدمين</li><li dir="RTL">ألم في عضلات أو عظام أو مفاصل الصدر</li><li dir="RTL">اضطراب في المعدة بعد تناول الطعام</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج الحلق</p><ul><li dir="RTL">تعب</li><li dir="RTL">ضعف</li><li dir="RTL">حكة</li><li dir="RTL">تغير في الصوت (بحة في الصوت)</li></ul><p dir="RTL">حدث لدى بعض المرضى المسنين اللذين تزيد أعمارهم عن 75 سنة شعور بالصداع (شائع التكرار) والتهاب المسالك البولية (شائع التكرار).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">في حال تعرضك لأي آثار جانبية، تحدث إلى طبيبك أو الصيدلي. يشمل<strong><em> </em></strong>ذلك أي آثار جانبية غير مذكورة في هذه النشرة. كما يمكنك الإبلاغ مباشرة عن الأعراض الجانبية (كما هو مذكور في قسم 6.ب). إبلاغك عن الأعراض الجانبية يساعد في توفير مزيد من المعلومات عن أمان الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ بعيداً عن مرأى ومتناول أيدي الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم الدواء بعد انتهاء تاريخ الصلاحية المطبوع على العلبة أو الشريط بعد &quot;EXP&quot;. يشير تاريخ الانتهاء إلى آخر يوم في الشهر المذكور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يُخزن فوق 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُخزن الكبسولات في العبوة الأصلية للحماية من الرطوبة ولا تُخرج الكبسولات إلا عند الاستخدام مباشرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي التخلص من كل جهاز استنشاق بعد 30 يوماً من الاستخدام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء إذا لاحظت تلفاً في العبوة أو علامات على<strong><em> </em></strong>العبث بها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الدواء عن طريق مياه الصرف الصحي أو النفايات المنزلية. إسأل الصيدلي عن الطرق المُثلى للتخلص من الدواء الغير مستعمل. من شأن هذه التدابير أن تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المادة الفعالة</strong> في سيبري بريزھيلر هي جليكوبيرونيوم بروميد. تحتوي كل كبسولة على 63 ميكروجرام من جليكوبيرونيوم بروميد (تعادل 50 ميكروجرام من جليكوبيرونيوم). الجرعة التي تصل (الجرعة التي تخرج من فتحة الفم لجهاز الاستنشاق) تعادل 44 ميكروجرام من جليكوبيرونيوم.</p><p dir="RTL"><strong>المكونات الأخرى</strong> في مسحوق الاستنشاق هي مونوهيدرات لاكتوز وستيرات ماغنيسيوم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">في هذه العبوة، ستجد جهاز استنشاق مع كبسولات في أشرطة منفطة. يحتوي كل شريط على إما 6 أو 10 كبسولات صلبة. الكبسولات شفافة وبرتقالية وتحتوي على مسحوق أبيض. مطبوع على الكبسولات رمز المنتج (GPL50) باللون الأسود، وشعار الشركة باللون الأسود &nbsp;(<!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_23" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:9.75pt;height:12.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/7/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="13" height="17" src="file:///C:/Users/alghasu1/AppData/Local/Temp/7/msohtmlclip1/01/clip_image002.jpg" />) &nbsp;مطبوع تحت خط أسود.</p><p dir="RTL">حجم العبوة المتوفر: حزمة واحدة تحتوي 30X1 كبسولات صلبة، مع جهاز استنشاق واحد.</p><p dir="RTL">قد تختلف ھذه المعلومات في بعض الدول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><br />مالك حق التَّسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.<br />www.Novartis.com&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Seebri Breezhaler 44 micrograms inhalation powder, hard capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 63 micrograms of glycopyrronium bromide equivalent to 50 micrograms of glycopyrronium.

Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 55 micrograms of glycopyrronium bromide equivalent to 44 micrograms of glycopyrronium.

Excipient(s) with known effect:
Each capsule contains 23.6 mg lactose (as monohydrate).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Inhalation powder, hard capsule

Transparent orange capsules containing a white powder, with the product code “GPL50” printed in black above and the company logo printed in black below a black bar.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Seebri Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dose is the inhalation of the content of one capsule once daily using the Seebri Breezhaler inhaler.</p><p>&nbsp;</p><p>Seebri Breezhaler is recommended to be administered, at the same time of the day each day. If a dose is missed, the next dose should be taken as soon as possible. Patients should be instructed not to take more than one dose in a day.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Elderly population</em></p><p>Seebri Breezhaler can be used at the recommended dose in elderly patients (75&nbsp;years of age and older) (see section&nbsp;4.8).</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>Seebri Breezhaler can be used at the recommended dose in patients with mild to moderate renal impairment. In patients with severe renal impairment or end‑stage renal disease requiring dialysis Seebri Breezhaler should be used only if the expected benefit outweighs the potential risk (see sections&nbsp;4.4 and 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No studies have been conducted in patients with hepatic impairment. Glycopyrronium is predominantly cleared by renal excretion and therefore no major increase in exposure is expected in patients with hepatic impairment.</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>There is no relevant use of Seebri Breezhaler in the paediatric population (under 18&nbsp;years) in the indication COPD.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>For inhalation use only.</p><p>&nbsp;</p><p>The capsules must be administered only using the Seebri Breezhaler inhaler (see section&nbsp;6.6).</p><p>&nbsp;</p><p>The capsules must not be swallowed.</p><p>&nbsp;</p><p>Patients should be instructed on how to administer the product correctly. Patients who do not experience improvement in breathing should be asked if they are swallowing the medicine rather than inhaling it.</p><p>&nbsp;</p><p>For instructions on use of the medicinal product before administration, see section&nbsp;6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Not for acute use</u></p><p>Seebri Breezhaler is a once‑daily, long‑term maintenance treatment and is not indicated for the initial treatment of acute episodes of bronchospasm, i.e.<em> </em>as a rescue therapy.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>Immediate hypersensitivity reactions have been reported after administration of Seebri Breezhaler. If signs suggesting allergic reactions occur, in particular, angioedema (including difficulties in breathing or swallowing, swelling of the tongue, lips, and face), urticaria or skin rash, Seebri Breezhaler should be discontinued immediately and alternative therapy instituted.</p><p>&nbsp;</p><p><u>Paradoxical bronchospasm</u></p><p>In clinical studies with Seebri Breezhaler, paradoxical bronchospasm was not observed. However, paradoxical bronchospasm has been observed with other inhalation therapy and can be life‑threatening. If this occurs, Seebri Breezhaler should be discontinued immediately and alternative therapy instituted.</p><p>&nbsp;</p><p><u>Anticholinergic effect</u></p><p>Seebri Breezhaler should be used with caution in patients with narrow‑angle glaucoma or urinary retention.</p><p>&nbsp;</p><p>Patients should be informed about the signs and symptoms of acute narrow‑angle glaucoma and should be informed to stop using Seebri Breezhaler and to contact their doctor immediately should any of these signs or symptoms develop.</p><p>&nbsp;</p><p><u>Patients with severe renal impairment</u></p><p>A moderate mean increase in total system exposure (AUC<sub>last</sub>) of up to 1.4‑fold was seen in subjects with mild and moderate renal impairment and up to 2.2‑fold in subjects with severe renal impairment and end‑stage renal disease. In patients with severe renal impairment (estimated glomerular filtration rate below 30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>), including those with end‑stage renal disease requiring dialysis, Seebri Breezhaler should be used only if the expected benefit outweighs the potential risk (see section&nbsp;5.2). These patients should be monitored closely for potential adverse reactions.</p><p>&nbsp;</p><p><u>Patients with a history of cardiovascular disease</u></p><p>Patients with unstable ischaemic heart disease, left ventricular failure, history of myocardial infarction, arrhythmia (excluding chronic stable atrial fibrillation), a history of long QT syndrome or whose QTc (Fridericia method) was prolonged (&gt;450&nbsp;ms for males or &gt;470&nbsp;ms for females) were excluded from the clinical trials, and therefore the experience in these patient groups is limited. Seebri Breezhaler should be used with caution in these patient groups.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The co‑administration of Seebri Breezhaler with other anticholinergic‑containing medicinal products has not been studied and is therefore not recommended.</p><p>&nbsp;</p><p>Although no formal drug interaction studies have been performed, Seebri Breezhaler has been used concomitantly with other medicinal products commonly used in the treatment of COPD without clinical evidence of drug interactions. These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids.</p><p>&nbsp;</p><p>In a clinical study in healthy volunteers, cimetidine, an inhibitor of organic cation transport which is thought to contribute to the renal excretion of glycopyrronium, increased total exposure (AUC) to glycopyrronium by 22% and decreased renal clearance by 23%. Based on the magnitude of these changes, no clinically relevant drug interaction is expected when glycopyrronium is co‑administered with cimetidine or other inhibitors of organic cation transport.</p><p>&nbsp;</p><p>Concomitant administration of Seebri Breezhaler and orally inhaled indacaterol, a beta<sub>2</sub>-adrenergic agonist, under steady‑state conditions of both active substances did not affect the pharmacokinetics of either medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no data from the use of Seebri Breezhaler in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section&nbsp;5.3). Glycopyrronium should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>It is unknown whether glycopyrronium bromide is excreted in human milk. However, glycopyrronium bromide (including its metabolites) was excreted in the milk of lactating rats (see section&nbsp;5.3). The use of glycopyrronium by breast‑feeding women should only be considered if the expected benefit to the woman is greater than any possible risk to the infant (see section&nbsp;5.3).</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Reproduction studies and other data in animals do not indicate a concern regarding fertility in either males or females (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glycopyrronium has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most common anticholinergic adverse reaction was dry mouth (2.4%). The majority of the reports of dry mouth were suspected to be related to the medicinal product and were mild, with none being severe.</p><p>&nbsp;</p><p>The safety profile is further characterised by other symptoms related to the anticholinergic effects, including signs of urinary retention, which were uncommon. Gastrointestinal effects including gastroenteritis and dyspepsia were also observed. Adverse reactions related to local tolerability included throat irritation, nasopharyngitis, rhinitis and sinusitis.</p><p>&nbsp;</p><p><u>Tabulated summary of adverse reactions</u></p><p>Adverse reactions reported during the first six months of two pooled pivotal Phase III trials of 6 and 12&nbsp;months duration are listed by MedDRA system organ class (Table&nbsp;1). Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse reaction is based on the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-fareast-font-family:"MS Gothic";mso-fareast-language:JA'><span
style='mso-element:field-begin'></span><span style='mso-spacerun:yes'> 
</span>SEQ Table \s 1 \* ARABIC<span style='mso-spacerun:yes'>  </span>\*
MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>1</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-fareast-font-family:"MS Gothic";mso-fareast-language:JA'><span
style='mso-element:field-end'></span></span></b><![endif]--><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions reported in the pooled 6-month database</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis<sup>1)</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Cystitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema<sup>2)</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache<sup>3)</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypoaesthesia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Atrial fibrillation</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Sinus congestion</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Productive cough</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Throat irritation</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Epistaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Paradoxical bronchospasm<sup>2)</sup></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Dysphonia<sup>2)</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastroenteritis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Dental caries</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus<sup>2)</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal chest pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection<sup>3)</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dysuria</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Urinary retention</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p><em>1) More frequent for glycopyrronium than placebo in the 12&nbsp;months database only.</em></p><p><em>2) Reports have been received from post-approval marketing experience in association with the use of Seebri Breezhaler. These were reported voluntarily from a population of uncertain size, and it is therefore not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure. Therefore the frequency was calculated from clinical trial experience.</em></p><p><em>3) Seen more frequently for glycopyrronium than placebo in elderly &gt;75&nbsp;years only.</em></p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>In the pooled 6-month database the frequency of dry mouth was 2.2% versus 1.1%, of insomnia 1.0% versus 0.8%, and of gastroenteritis 1.4% versus 0.9%,<strong> </strong>for Seebri Breezhaler and placebo respectively.</p><p>&nbsp;</p><p>Dry mouth was reported mainly during the first 4&nbsp;weeks of treatment with a median duration of four weeks in the majority of patients. However in 40% of cases symptoms continued for the entire 6-month period. No new cases of dry mouth were reported in months 7‑12.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>--<em>To reports any side effect(s): </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia: </em></strong></p><p>--The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States: </em></strong></p><p>-- Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>High doses of glycopyrronium may lead to anticholinergic signs and symptoms for which symptomatic treatment may be indicated.</p><p>&nbsp;</p><p>Acute intoxication by inadvertent oral ingestion of Seebri Breezhaler capsules is unlikely due to the low oral bioavailability (about 5%).</p><p>&nbsp;</p><p>Peak plasma levels and total systemic exposure following intravenous administration of 150&nbsp;micrograms glycopyrronium bromide (equivalent to 120&nbsp;micrograms glycopyrronium) in healthy volunteers were respectively about 50-fold and 6-fold higher than the peak and total exposure at steady‑state achieved with the recommended dose (44&nbsp;micrograms once daily) of Seebri Breezhaler and were well tolerated.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for obstructive airway diseases, anticholinergics, ATC code: R03BB06</p><p><em>&nbsp;</em></p><p><u>Mechanism of action</u></p><p>Seebri Breezhaler is an inhaled long‑acting muscarinic receptor antagonist (anticholinergic) for once‑daily maintenance bronchodilator treatment of COPD. Parasympathetic nerves are the major bronchoconstrictive neural pathway in airways, and cholinergic tone is the key reversible component of airflow obstruction in COPD. Glycopyrronium works by blocking the bronchoconstrictor action of acetylcholine on airway smooth muscle cells, thereby dilating the airways.</p><p>&nbsp;</p><p>Glycopyrronium bromide is a high affinity muscarinic receptor antagonist. A greater than 4-fold selectivity for the human M3 receptors over the human M2 receptor has been demonstrated using radioligand binding studies. It has a rapid onset of action as evidenced by observed receptor association/dissociation kinetic parameters and the onset of action after inhalation in clinical studies.</p><p>&nbsp;</p><p>The long duration of action can be partly attributed to sustained concentrations of active substance in the lung as reflected by the prolonged terminal elimination half‑life of glycopyrronium after inhalation via the Seebri Breezhaler inhaler in contrast to the half life after intravenous administration (see section&nbsp;5.2).</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>The clinical Phase III development programme included two phase III studies: a 6-month placebo‑controlled study and a 12-month placebo and active‑controlled (open label tiotropium 18&nbsp;micrograms once daily) study, both in patients with clinical diagnosis of moderate to severe COPD.</p><p>&nbsp;</p><p><em>Effects on lung function</em></p><p>Seebri Breezhaler 44&nbsp;micrograms once daily provided consistently statistically significant improvement in lung function (forced expiratory volume in one second, FEV<sub>1</sub>, forced vital capacity, FVC, and inspiratory capacity, IC) in a number of clinical studies. In phase III studies, bronchodilator effects were seen within 5&nbsp;minutes after the first dose and were maintained over the 24-hour dosing interval from the first dose. There was no attenuation of the bronchodilator effect over time in the 6- and 12-month studies. The magnitude of the effect was dependent on the degree of reversibility of airflow limitation at baseline (tested by administration of a short-acting muscarinic antagonist bronchodilator): Patients with the lowest degree of reversibility at baseline (&lt;5%) generally exhibited a lower bronchodilator response than patients with a higher degree of reversibility at baseline (&ge;5%). At 12&nbsp;weeks (primary endpoint), Seebri Breezhaler increased trough FEV<sub>1</sub> by 72&nbsp;ml in patients with the lowest degree of reversibility (&lt;5%) and by 113&nbsp;ml in those patients with a higher degree of reversibility at baseline (&ge;5%) compared to placebo (both p&lt;0.05).</p><p>&nbsp;</p><p>In the 6-month study, Seebri Breezhaler increased FEV<sub>1</sub> after the first dose with an improvement of 93&nbsp;ml within 5&nbsp;minutes and 144&nbsp;ml within 15&nbsp;minutes of dosing, compared to placebo (both p&lt;0.001). In the 12-month study, the improvements were 87&nbsp;ml at 5&nbsp;minutes and 143&nbsp;ml at 15&nbsp;minutes (both p&lt;0.001). In the 12-month study, Seebri Breezhaler produced statistically significant improvements in FEV<sub>1</sub> compared to tiotropium in the first 4&nbsp;hours after dosing on day&nbsp;1 and at week&nbsp;26, and numerically greater values for FEV<sub>1</sub> in the first 4&nbsp;hours after dosing than tiotropium at week&nbsp;12 and week&nbsp;52.</p><p>&nbsp;</p><p>The values for FEV<sub>1</sub> at the end of the dosing interval (24&nbsp;h post dose) were similar between the first dose and those seen after 1&nbsp;year of dosing. At 12&nbsp;weeks (primary endpoint), Seebri Breezhaler increased trough FEV<sub>1</sub> by 108&nbsp;ml in the 6‑month study and by 97&nbsp;ml in the 12‑month study compared to placebo (both p&lt;0.001). In the 12-month study, the improvement versus placebo for tiotropium was 83&nbsp;ml (p&lt;0.001).</p><p><u>&nbsp;</u></p><p><em>Symptomatic outcomes</em></p><p>Seebri Breezhaler administered at 44&nbsp;micrograms once daily statistically significantly reduced breathlessness as evaluated by the Transitional Dyspnoea Index (TDI). In a pooled analysis of the 6- and 12-month pivotal studies a statistically significantly higher percentage of patients receiving Seebri Breezhaler responded with a 1&nbsp;point or greater improvement in the TDI focal score at week&nbsp;26 compared to placebo (58.4% and 46.4% respectively, p&lt;0.001). These findings were similar to those seen in patients receiving tiotropium, 53.4% of whom responded with 1&nbsp;point or greater improvement (p=0.009 compared to placebo).</p><p>&nbsp;</p><p>Seebri Breezhaler once daily has also shown a statistically significant effect on health‑related quality of life measured using the St. George&rsquo;s Respiratory Questionnaire (SGRQ). A pooled analysis of the 6- and 12-month pivotal studies found a statistically significantly higher percentage of patients receiving Seebri Breezhaler responded with a 4&nbsp;point or greater improvement in SGRQ compared to placebo at week&nbsp;26 (57.8% and 47.6% respectively, p&lt;0.001). For patients receiving tiotropium, 61.0% responded with a 4 point or greater improvement in SGRQ (p=0.004 compared to placebo).</p><p>&nbsp;</p><p><em>COPD exacerbations reduction</em></p><p>COPD exacerbation data was collected in the 6- and 12&ndash;month pivotal studies. In both studies, the percentage of patients experiencing a moderate or severe exacerbation (defined as requiring treatment with systemic corticosteroids and/or antibiotics or hospitalisation) was reduced. In the 6-month study, the percentage of patients experiencing a moderate or severe exacerbation was 17.5% for Seebri Breezhaler and 24.2% for placebo (Hazard ratio: 0.69, p=0.023), and in the 12-month study it was 32.8% for Seebri Breezhaler and 40.2% for placebo (Hazard ratio: 0.66, p=0.001). In a pooled analysis of the first 6&nbsp;months of treatment in the 6- and 12-month studies, compared to placebo Seebri Breezhaler statistically significantly prolonged time to first moderate or severe exacerbation and reduced the rate of moderate or severe COPD exacerbations (0.53&nbsp;exacerbations/year versus 0.77exacerbations /year, p&lt;0.001). The pooled analysis also showed fewer patients treated with Seebri Breezhaler than with placebo experienced an exacerbation requiring hospitalisation (1.7% versus 4.2%, p=0.003).</p><p>&nbsp;</p><p><em>Other effects</em></p><p>Seebri Breezhaler once daily statistically significantly reduced the use of rescue medication (salbutamol) by 0.46&nbsp;puffs per day (p=0.005) over 26&nbsp;weeks and by 0.37&nbsp;puffs per day (p=0.039) over 52&nbsp;weeks, compared to placebo for the 6- and 12-month studies, respectively.</p><p>&nbsp;</p><p>In a 3‑week study where exercise tolerance was tested via cycle ergometer at submaximal (80%) workload (submaximal exercise tolerance test), Seebri Breezhaler, dosed in the morning, reduced dynamic hyperinflation and improved the length of time exercise could be maintained from the first dose onwards. On the first day of treatment inspiratory capacity under exercise was improved by 230&nbsp;ml and exercise endurance time was improved by 43&nbsp;seconds (an increase of 10%) compared to placebo. After three weeks of treatment the improvement in inspiratory capacity with Seebri Breezhaler was similar to the first day (200&nbsp;ml), exercise endurance time however had increased by 89&nbsp;seconds (an increase of 21%) compared to placebo. Seebri Breezhaler was found to decrease dyspnoea and leg discomfort when exercising as measured using Borg scales. Seebri Breezhaler also reduced dyspnoea at rest measured using the Transitional Dyspnoea Index.</p><p>&nbsp;</p><p><em>Secondary pharmacodynamic effects</em></p><p>No change in mean heart rate or QTc interval was observed with Seebri Breezhaler in doses up to 176&nbsp;micrograms in COPD patients. In a thorough QT study in 73&nbsp;healthy volunteers, a single inhaled dose of glycopyrronium 352&nbsp;micrograms (8&nbsp;times the therapeutic dose) did not prolong the QTc interval and slightly reduced heart rate (maximal effect ‑5.9&nbsp;bpm; average effect over 24&nbsp;hours ‑2.8&nbsp;bpm) when compared to placebo. The effect on heart rate and QTc interval of 150&nbsp;micrograms glycopyrronium bromide (equivalent to 120&nbsp;micrograms glycopyrronium) administered intravenously was investigated in young healthy subjects. Peak exposures (C<sub>max</sub>) about 50-fold higher than after inhalation of glycopyrronium 44&nbsp;micrograms at steady state were achieved and did not result in tachycardia or QTc prolongation. A slight reduction in heart rate (mean difference over 24&nbsp;h ‑2&nbsp;bpm when compared to placebo), which is a known effect of low exposures to anticholinergic compounds in young healthy subjects, was observed.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Seebri Breezhaler in all subsets of the paediatric population in COPD (see section&nbsp;4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Following oral inhalation using the Seebri Breezhaler inhaler, glycopyrronium was rapidly absorbed and reached peak plasma levels at 5&nbsp;minutes post dose.</p><p>&nbsp;</p><p>The absolute bioavailability of glycopyrromium inhaled via Seebri Breezhaler was estimated to be about 45% of the delivered dose. About 90% of systemic exposure following inhalation is due to lung absorption and 10% is due to gastrointestinal absorption.</p><p>&nbsp;</p><p>In patients with COPD, pharmacokinetic steady‑state of glycopyrronium was reached within one week of the start of treatment. The steady‑state mean peak and trough plasma concentrations of glycopyrronium for a 44&nbsp;micrograms once‑daily dosing regimen were 166&nbsp;picograms/ml and 8&nbsp;picograms/ml, respectively. Steady‑state exposure to glycopyrronium (AUC over the 24-hour dosing interval) was about 1.4- to 1.7-fold higher than after the first dose.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>After intravenous dosing, the steady‑state volume of distribution of glycopyrronium was 83&nbsp;litres and the volume of distribution in the terminal phase was 376&nbsp;litres. The apparent volume of distribution in the terminal phase following inhalation was almost 20-fold larger, which reflects the much slower elimination after inhalation. The <em>in vitro</em> human plasma protein binding of glycopyrronium was 38% to 41% at concentrations of 1 to 10&nbsp;nanograms/ml.</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p><em>In vitro</em> metabolism studies showed consistent metabolic pathways for glycopyrronium bromide between animals and humans. Hydroxylation resulting in a variety of mono‑and bis‑hydroxylated metabolites and direct hydrolysis resulting in the formation of a carboxylic acid derivative (M9) were seen. <em>In vivo</em>, M9 is formed from the swallowed dose fraction of inhaled glycopyrronium bromide. Glucuronide and/or sulfate conjugates of glycopyrronium were found in urine of humans after repeated inhalation, accounting for about 3% of the dose.</p><p>&nbsp;</p><p>Multiple CYP isoenzymes contribute to the oxidative biotransformation of glycopyrronium. Inhibition or induction of the metabolism of glycopyrronium is unlikely to result in a relevant change of systemic exposure to the active substance.</p><p>&nbsp;</p><p><em>In</em><em> vitro</em> inhibition studies demonstrated that glycopyrronium bromide has no relevant capacity to inhibit CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4/5, the efflux transporters MDR1, MRP2 or MXR, and the uptake transporters OCT1 or OCT2. <em>In vitro</em> enzyme induction studies did not indicate a clinically relevant induction by glycopyrronium bromide for cytochrome P450 isoenzymes, or for UGT1A1 and the transporters MDR1 and MRP2.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>After intravenous administration of [<sup>3</sup>H]-labelled glycopyrronium bromide to humans, the mean urinary excretion of radioactivity in 48&nbsp;hours amounted to 85% of the dose. A further 5% of the dose was found in the bile.</p><p>&nbsp;</p><p>Renal elimination of parent drug accounts for about 60 to 70% of total clearance of systemically available glycopyrronium whereas non‑renal clearance processes account for about 30 to 40%. Biliary clearance contributes to the non‑renal clearance, but the majority of non‑renal clearance is thought to be due to metabolism.</p><p>&nbsp;</p><p>Mean renal clearance of glycopyrronium following inhalation was in the range of 17.4 and 24.4&nbsp;litres/h. Active tubular secretion contributes to the renal elimination of glycopyrronium. Up to 23% of the delivered dose was found in urine as parent drug.</p><p>&nbsp;</p><p>Glycopyrronium plasma concentrations declined in a multi‑phasic manner. The mean terminal elimination half‑life was much longer after inhalation (33 to 57&nbsp;hours) than after intravenous (6.2&nbsp;hours) and oral (2.8&nbsp;hours) administration. The elimination pattern suggests sustained lung absorption and/or transfer of glycopyrronium into the systemic circulation at and beyond 24&nbsp;hours after inhalation.</p><p>&nbsp;</p><p><u>Linearity/non‑linearity</u></p><p>In COPD patients both systemic exposure and total urinary excretion of glycopyrronium at pharmacokinetic steady state increased about dose‑proportionally over the dose range of 44 to 176&nbsp;micrograms.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>A population pharmacokinetic analysis of data in COPD patients identified body weight and age as factors contributing to inter‑patient variability in systemic exposure. Seebri Breezhaler 44&nbsp;micrograms once daily can be safely used in all age and body weight groups.</p><p>&nbsp;</p><p>Gender, smoking status and baseline FEV<sub>1</sub> had no apparent effect on systemic exposure.</p><p>&nbsp;</p><p>There were no major differences in total systemic exposure (AUC) between Japanese and Caucasian subjects following inhalation of glycopyrronium bromide. Insufficient pharmacokinetic data is available for other ethnicities or races.</p><p>&nbsp;</p><p><em>Patients with hepatic impairment</em></p><p>Clinical studies have not been conducted in patients with hepatic impairment. Glycopyrronium is cleared predominantly from the systemic circulation by renal excretion. Impairment of the hepatic metabolism of glycopyrronium is not thought to result in a clinically relevant increase of systemic exposure.</p><p>&nbsp;</p><p><em>Patients with renal impairment</em></p><p>Renal impairment has an impact on the systemic exposure to glycopyrronium bromide. A moderate mean increase in total systemic exposure (AUC<sub>last</sub>) of up to 1.4-fold was seen in subjects with mild and moderate renal impairment and up to 2.2-fold in subjects with severe renal impairment and end‑stage renal disease. In COPD patients with mild and moderate renal impairment (estimated glomerular filtration rate, eGFR &ge;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>) Seebri Breezhaler can be used at the recommended dose. In patients with severe renal impairment (eGFR &lt;30&nbsp;ml/min/1.73 m<sup>2</sup>), including those with end‑stage renal disease requiring dialysis, Seebri Breezhaler should only be used in the expected benefit outweighs the potential risk (see section&nbsp;4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Non‑clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</p><p>&nbsp;</p><p>Effects attributable to the muscarinic receptor antagonist properties of glycopyrronium bromide included mild to moderate increases in heart rate in dogs, lens opacities in rats and, reversible changes associated with reduced glandular secretions in rats and dogs. Mild irritancy or adaptive changes in the respiratory tract were seen in rats. All these findings occurred at exposures sufficiently in excess of those anticipated in humans.</p><p>&nbsp;</p><p>Glycopyrronium was not teratogenic in rats or rabbits following inhalation administration. Fertility and pre- and post‑natal development were not affected in rats. Glycopyrronium bromide and its metabolites did not significantly cross the placental barrier of pregnant mice, rabbits and dogs. Glycopyrronium bromide (including its metabolites) was excreted into the milk of lactating rats and reached up to 10-fold higher concentrations in the milk than in the blood of the dam.</p><p>&nbsp;</p><p>Genotoxicity studies did not reveal any mutagenic or clastogenic potential for glycopyrronium bromide. Carcinogenicity studies in transgenic mice using oral administration and in rats using inhalation administration revealed no evidence of carcinogenicity at systemic exposures (AUC) of approximately 53-fold higher in mice and 75-fold higher in rats than the maximum recommended dose of 44&nbsp;micrograms once daily for humans.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content</u></p><p>Lactose monohydrate</p><p>Magnesium stearate</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 month

Each inhaler should be disposed of after 30 days of use.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p>The capsules must always be stored in the blister to protect from moisture and only removed immediately before use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Seebri Breezhaler is a single‑dose inhaler. Inhaler body and cap are made from acrylonitrile butadiene styrene, push buttons are made from methyl metacrylate acrylonitrile butadiene styrene. Needles and springs are made from stainless steel. Each blister contains either 6 or 10&nbsp;hard capsules.</p><p>&nbsp;</p><p>PA/Alu/PVC &ndash; Alu perforated unit-dose blister</p><p>&nbsp;</p><p>Single pack containing 30x1&nbsp;hard capsules, with one inhaler.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The inhaler provided with each new prescription should be used. Each inhaler should be disposed of after 30&nbsp;days of use.</p><p>&nbsp;</p><p><u>Instructions for handling and use</u></p><p><em>&nbsp;</em></p><table border="0" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>How to use your inhaler</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Pull off the cap.</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Open inhaler:</strong></p><p>Hold the base of the inhaler firmly and tilt the mouthpiece. This opens the inhaler.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Prepare capsule:</strong></p><p>Separate one of the blisters from the blister card by tearing along the perforation.</p><p>Take one blister and peel away the protective backing to expose the capsule.</p><p>&nbsp;</p><p>Do not push capsule through foil.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Remove a capsule:</strong></p><p>Capsules should always be stored in the blister and only removed immediately before use.</p><p>With dry hands, remove capsule from the blister.</p><p>Do not swallow the capsule.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Insert capsule:</strong></p><p>Place the capsule into the capsule chamber.</p><p>&nbsp;</p><p><strong>Never place a capsule directly into the mouthpiece.</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Close the inhaler:</strong></p><p>Close the inhaler until you hear a &ldquo;<strong>click</strong>&rdquo;.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Pierce the capsule:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the inhaler upright with the mouthpiece pointing up.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pierce the capsule by firmly pressing together both side buttons at the same time. <strong>Do this only once.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should hear a &ldquo;<strong>click</strong>&rdquo; as the capsule is being pierced.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Release the side buttons fully.</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Breathe out:</strong></p><p>Before placing the mouthpiece in your mouth, breathe out fully.</p><p>&nbsp;</p><p><strong>Do not blow into the mouthpiece.</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Inhale the medicine:</strong></p><p>To breathe the medicine deeply into your airways:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the inhaler as shown in the picture. The side buttons should be facing left and right. Do not press the side buttons.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place the mouthpiece in your mouth and close your lips firmly around it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathe in rapidly but steadily, as deeply as you can. <strong>Do not press the side buttons.</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Note:</strong></p><p>As you breathe in through the inhaler, the capsule spins around in the chamber and you should hear a whirring noise. You will experience a sweet flavour as the medicine goes into your lungs.</p><p>&nbsp;</p><p><strong>If you do not hear a whirring noise</strong>:</p><p>The capsule may be stuck in the capsule chamber. If this happens:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Open the inhaler and carefully loosen the capsule by tapping the base of the inhaler. <strong>Do not press the side buttons.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhale the medicine again by repeating steps&nbsp;9 and 10.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Hold breath:</strong></p><p><strong>After you have inhaled the medicine:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hold your breath</strong> for at least 5‑10&nbsp;seconds or as long as you comfortably can while taking the inhaler out of your mouth.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Then breathe out.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Open the inhaler to see if any powder is left in the capsule.</p><p>&nbsp;</p><p><strong>If there is powder left in the capsule:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Close the inhaler.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Repeat steps&nbsp;9 to 12.</p><p>&nbsp;</p><p>Most people are able to empty the capsule with one or two inhalations.</p><p>&nbsp;</p><p><strong>Additional information</strong></p><p>Some people occasionally cough briefly soon after inhaling a medicine. If you do, don&rsquo;t worry. As long as the capsule is empty, you have received enough of your medicine.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>After you have finished taking</strong> your daily dose of Seebri Breezhaler:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Open the mouthpiece again, and remove the empty capsule by tipping it out of the capsule chamber. Put the empty capsule in your household waste.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Close the inhaler and replace the cap.</p><p>&nbsp;</p><p><strong>Do not store the capsules in the Seebri Breezhaler<em> </em>inhaler.</strong></p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>